{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014223","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.753582+00:00","generated_at":"2026-06-24T05:02:57.859187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q2 2022 revenue $18.5M; cash $580.8M; FT516 RMAT meeting set","bullets":["Q2 2022 collaboration revenue $18.5M from Janssen and ONO; R&D expense $81.3M, G&A $20.4M; cash $580.8M at June 30.","FT516 RMAT meeting with FDA scheduled for 3Q22 to discuss registrational pathways for relapsed/refractory aggressive B-cell lymphoma.","First patient dosed with FT536 CAR MICA/B NK cell product candidate for advanced solid tumors; multi-dose enrollment ongoing.","Janssen exercised commercial option for first iPSC-derived CAR NK collaboration program; first IND planned 2H22.","Expanded ONO collaboration: second solid tumor antigen program added, both CAR NK and CAR T candidates in development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014223","json":"https://secwatch.observer/filing/0000950170-22-014223.json","markdown":"https://secwatch.observer/filing/0000950170-22-014223.md","text":"https://secwatch.observer/filing/0000950170-22-014223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022014223/0000950170-22-014223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022014223/fate-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:02:57.859187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}